表紙
市場調查報告書
商品編碼
365772

血管生成素1受體:開發中產品分析

Angiopoietin 1 Receptor - Pipeline Review, H2 2019

出版日期: | 出版商: Global Markets Direct | 英文 141 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供以血管生成素1受體為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

血管生成素1受體 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Aerpio Therapeutics, Inc.
  • Deciphera Pharmaceuticals, LLC
  • Eddingpharm
  • Exelixis, Inc.
  • Pfizer Inc.
  • PharmAbcine, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC1937TDB

Summary:

According to the recently published report 'Angiopoietin 1 Receptor - Pipeline Review, H2 2019'; Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Angiopoietin-1 receptor or CD202B is a protein encoded by the TEK gene.It regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton. It also maintains of vascular quiescence. It has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. It is required for normal angiogenesis and heart development during embryogenesis. It is required for post-natal hematopoiesis.

The report 'Angiopoietin 1 Receptor - Pipeline Review, H2 2019' outlays comprehensive information on the Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 3, 1, 7, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Male Health, Non Malignant Disorders and Respiratory which include indications Gastric Cancer, Metastatic Colorectal Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Endometrial Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Adenocarcinoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Colorectal Cancer, Esophageal Cancer, Ewing Sarcoma, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Uveal Melanoma, Open-Angle Glaucoma, Osteosarcoma, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Tumor, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Respiratory Distress Syndrome, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Asthma, Atopic Dermatitis (Atopic Eczema), Carcinoid Tumor, Choroidal Neovascularization, Diabetic Foot Ulcers, Diabetic Ischemic Foot Ulcers, Diabetic Macular Edema, Diabetic Neuropathic Foot Ulcers, Epithelial Ovarian Cancer, Erectile Dysfunction, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glaucoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Leiomyosarcoma, Liposarcoma, Liver Cancer, Lung Cancer, Macular Edema, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myocardial Infarction, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Non-Rhabdomyosarcoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Osteolytic Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Paraganglioma (Glomus Jugulare Tumor), Penile Cancer, Peritoneal Cancer, Pheochromocytoma, Plexiform Neurofibroma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)
  • The report reviews Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Overview
    • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • AsclepiX Therapeutics Inc
    • Bayer AG
    • Deciphera Pharmaceuticals Inc
    • Eddingpharm Inc
    • Eli Lilly and Co
    • Exelixis Inc
    • Pfizer Inc
    • PharmAbcine Inc
    • Q BioMed Inc
    • Samjin Pharm Co Ltd
    • Teva Pharmaceutical Industries Ltd
  • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Drug Profiles
    • ACX-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-185 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-216 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cabometyx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEP-11981 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDP-317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAN-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAN-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexmetinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rebastinib tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • regorafenib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SJP-1601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit VEGFR2, TIE 2 and EPHB4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize TIE2 for Glaucoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VDAU-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Dormant Products
  • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Discontinued Products
  • Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AsclepiX Therapeutics Inc, H2 2019
  • Pipeline by Bayer AG, H2 2019
  • Pipeline by Deciphera Pharmaceuticals Inc, H2 2019
  • Pipeline by Eddingpharm Inc, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Exelixis Inc, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by PharmAbcine Inc, H2 2019
  • Pipeline by Q BioMed Inc, H2 2019
  • Pipeline by Samjin Pharm Co Ltd, H2 2019
  • Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019